Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFRm Advanced Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07058519
What this trial is testing

Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Who this might be right for
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital 250
Early research (Phase 1)Study completedNCT02503774
What this trial is testing

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Who this might be right for
Solid Tumors
MedImmune LLC 192
Early research (Phase 1)Active Not RecruitingNCT02143466
What this trial is testing

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Who this might be right for
Advanced Non Small Cell Lung Cancer
AstraZeneca 344
Early research (Phase 1)Study completedNCT02157883
What this trial is testing

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT05801029
What this trial is testing

Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Large-scale testing (Phase 3)Active Not RecruitingNCT05009836
What this trial is testing

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Hutchmed 412
Not applicableStudy completedNCT03761901
What this trial is testing

Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 141
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Large-scale testing (Phase 3)Active Not RecruitingNCT05338970
What this trial is testing

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Who this might be right for
Nonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion
Daiichi Sankyo 586
Early research (Phase 1)Not Yet RecruitingNCT06218940
What this trial is testing

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

Who this might be right for
NSCLC Stage IV
Newsoara Biopharma Co., Ltd. 40
Testing effectiveness (Phase 2)Ended earlyNCT06186076
What this trial is testing

Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell LungEGFR Mutant Advanced Non-Small Cell Lung Cancer
Therapex Co., Ltd 19
Testing effectiveness (Phase 2)Looking for participantsNCT06631989
What this trial is testing

Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc. 100
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Testing effectiveness (Phase 2)Study completedNCT04770688
What this trial is testing

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR MutationLocally Advanced Solid TumorMetastatic Cancer+1 more
Shanghai Chest Hospital 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04606771
What this trial is testing

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 30
Testing effectiveness (Phase 2)UnknownNCT06334757
What this trial is testing

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Henan Cancer Hospital 46
Not applicableNot Yet RecruitingNCT07680907
What this trial is testing

A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen-Cilag Farmaceutica Ltda. 250
Early research (Phase 1)Study completedNCT02908750
What this trial is testing

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 24
Large-scale testing (Phase 3)Study completedNCT02474355
What this trial is testing

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 3,017
Next Page